Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Copenhagen University Hospital at Herlev.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Copenhagen University Hospital at Herlev
ClinicalTrials.gov Identifier:
NCT01132339
First received: May 25, 2010
Last updated: May 12, 2011
Last verified: May 2011
  Purpose

Rationale:

Contrast agents are important tools for MR/CT- examinations, when it comes to diagnosing diseases. But despite their frequent use in Denmark, they are not free of serious and potentially fatal adverse reactions. Examples of this are contrast-induced nephropathy (CIN) and nephrogenic systemic fibrosis (NSF). Therefore, it is extremely important to clarify if these adverse reactions are actually directly related to the use of contrast agents or to MR/CT- examinations.

Objective:

To prospectively assess the incidence of adverse reactions of iodine-containing CT and gadolinium- based MR contrast agents in a prospective design. A control group examined without the use of contrast agent will be included, so that the study can illuminate reported adverse events related to contrast agents and CT/MR- examinations. This project will in the long term mean that, any significant and life-threatening delayed adverse reactions will be discovered earlier and hence it will be more likely to treat the patients in good time for these adverse reactions.

The following series of hypotheses will be investigated in this study:

  1. Renal as well as non-renal adverse reactions occurring are related to the use of contrast agent in MR-/CT-examination.
  2. CIN occurs in patients undergoing a MR-/CT-examination with contrast agent.

Methods:

Approvals are obtained from The Copenhagen County Committee on Biomedical Research Ethics and Danish Data Protection Agency. A total of 1600 patients will be included from Department of Radiology at Herlev Hospital, where all the MR- and CT examinations will be performed. Patients will be divided into four groups (a, b, c and d) with 400 patients in each group. Group a and c (case group) undergo respectively MR and CT examination with contrast agent While group b and d (control group) will undergo respectively MR and CT examination without the use of contrast agent. For each patient the following will be recorded: Risk factors, renal function (eGFR) before and 72 hours after MR/CT- examination as well as the incidence of immediate reactions (within 30 min.). Furthermore, patients have to answer a questionnaire 72 hours and 1 month after MR/CT- examination about the severity and frequency of adverse reactions to contrast media.


Condition
Contrast Induced Nephropathy
Nephrogenic Systemic Fibrosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Clinical Trial to Investigate Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)

Resource links provided by NLM:


Further study details as provided by Copenhagen University Hospital at Herlev:

Estimated Enrollment: 1600
Study Start Date: May 2010
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Enhanced MR (case group)
those with an exposure to gadolinium-based contrast agent
Unenhanced MR (control group)
those without an exposure to gadolinium-based contrast agent
Unenhanced CT (control group)
those without an exposure to iodine-containing contrast agent
Enhanced CT (case group)
those with an exposure to iodine-containing contrast agent

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The population will be selected from Herlev Hospital, Department of Radiology. Patients referred to an MR/CT-examination will be offered participation in this study.

Criteria

Inclusion Criteria:

  • Patients who are referred to a MR/CT-examination at Herlev Hospital, Department of Radiology
  • Age > 18 years

Exclusion Criteria:

  • Age < 18 years
  • Patients allergic to gadolinium-based and iodine-containing contrast agents are not included in the case group
  • Increased metabolism (hyperthyroidism)
  • Dementia
  • Pregnancy / lactation
  • Patients who have undergone MR/CT- examinations within the last month prior to the actual examination
  • New MR/CT-examination (enhanced and unenhanced) in the observation period (one month).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01132339

Contacts
Contact: Manal Azzouz, MSc Pharmacy +45 44 88 43 91 MAZZ0001@heh.regionh.dk
Contact: Jørgen H. Andersen, M.Sc. +45 44 88 47 82 j.hvidsten@heh.regionh.dk

Locations
Denmark
Department of Diagnostic Radiology,Copenhagen University Hospital Herlev Recruiting
Herlev, Denmark, 2730
Contact: Manal Azzouz, MSc Pharmacy     +45 44 88 43 91     MAZZ0001@heh.regionh.dk    
Contact: Jørgen H Andersen, M.Sc.     +45 44 88 47 82     j.hvidsten@heh.regionh.dk    
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Investigators
Principal Investigator: Manal Azzouz, MSc Pharmacy Department of Diagnostic Radiology,Copenhagen University Hospital Herlev
Study Director: Henrik S Thomsen Department of Diagnostic Radiology,Copenhagen University Hospital Herlev
  More Information

Publications:

Responsible Party: Henrik S.Thomsen, Department of Radiology, Herlev Hospital
ClinicalTrials.gov Identifier: NCT01132339     History of Changes
Other Study ID Numbers: H-1-2010-011
Study First Received: May 25, 2010
Last Updated: May 12, 2011
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by Copenhagen University Hospital at Herlev:
Adverse reactions to Gadolinium-based contrast agents.
Adverse reactions to Iodine-containing contrast agents.

Additional relevant MeSH terms:
Fibrosis
Kidney Diseases
Nephrogenic Fibrosing Dermopathy
Pathologic Processes
Urologic Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 16, 2013